Application for clinical application of two psychotropic drugs in Huahai pharmaceutical industry and acceleration of application for domestic preparations

Astak news agency reported on January 16 that the clinical application of olanzapine fluoxetine capsule and quetiapine fumarate sustained-release tablets, two psychotropic drugs of Huahai Pharmaceutical (600521 SH), was accepted according to the website information of CFDA Huahai Pharmaceutical Co., Ltd is mainly engaged in Puli and sartan APIs Domestic preparations are an important starting point for the company's transformation from APIs to preparations The company plans to achieve an operating revenue of 3 billion yuan by 2016 It is worth mentioning that the number of approvals is the key to determine the scale of the pharmaceutical business Since this year, Huahai pharmaceutical has frequently applied for pharmaceutical preparations Last week, three generic pharmaceutical applications of the company were accepted Olanzapine fluoxetine capsule is a compound preparation for the treatment of depression, which has the advantages of good clinical effect, rapid onset, etc., and does not increase side effects At present, there is no manufacturer of the drug in China, and only one enterprise has applied for clinical trials except Huahai pharmaceutical Quetiapine fumarate is an atypical antipsychotic drug It is a first-line clinical drug for schizophrenia The original manufacturer is AstraZeneca The domestic pharmaceutical manufacturers are only the first pharmaceutical in Suzhou and Dongting pharmaceutical in Hunan, both of which are ordinary tablets.